The U.S. Food and Drug Administration is preparing to reverse a previous rejection of a rare-disease treatment developed by Regenxbio, according to a report published Monday by the Wall Street Journal.
No further details about the specific therapy, the conditions it targets, or the expected timeline for the reversal were included in the report.
